Business Context and Reporting Period
This Form 8-K Current Report from United States Antimony Corp (UAMY) covers the results of the 2026 Annual Shareholders Meeting held on June 12, 2026. The company is incorporated in Texas and its common stock trades on NYSE American and NYSE Texas.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
All three proposals submitted to shareholders were approved. The specific voting outcomes were:
- Proposal 1 (Election of Directors): All seven nominees were elected. Notable voting splits included Dr. Blaise Aguirre (26.2M For, 22.9M Abstain) and Michael A. McManus (38.5M For, 10.6M Abstain), while others received significantly higher "For" votes with lower abstentions.
- Proposal 2 (Authorized Share Increase): Shareholders approved an amendment to the Certificate of Formation to increase the number of authorized shares. Votes: 73.5M For, 15.3M Against, 935k Abstain.
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes: 68.1M For, 462k Against, 21.2M Abstain.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It references definitive proxy statements filed on April 20, April 27, and June 8, 2026, for further details on the proposals.
Investor Verification Checklist
- Verify the impact of the approved increase in authorized shares on potential future dilution.
- Review the high abstention rates for certain director nominees (e.g., Dr. Blaise Aguirre) to understand shareholder sentiment.
- Confirm the independence and qualifications of the newly ratified auditor, Sadler, Gibb & Associates, LLC.
- Check the referenced Schedule 14A filings for detailed rationale behind the share authorization amendment.